Publication

Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit?

Pinto, YM., van Geel, PP., Alkfaji, H., van Veldhuisen, DJ. & van Gilst, WH., Aug-1999, In : Journal of Cardiovascular Pharmacology. 34, p. S13-S17 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Pinto, YM., van Geel, PP., Alkfaji, H., van Veldhuisen, DJ., & van Gilst, WH. (1999). Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit? Journal of Cardiovascular Pharmacology, 34, S13-S17.

Author

Pinto, YM ; van Geel, PP ; Alkfaji, H ; van Veldhuisen, DJ ; van Gilst, WH. / Dosing of ACE inhibitors in left ventricular dysfunction : Does current clinical dosing provide optimal benefit?. In: Journal of Cardiovascular Pharmacology. 1999 ; Vol. 34. pp. S13-S17.

Harvard

Pinto, YM, van Geel, PP, Alkfaji, H, van Veldhuisen, DJ & van Gilst, WH 1999, 'Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit?', Journal of Cardiovascular Pharmacology, vol. 34, pp. S13-S17.

Standard

Dosing of ACE inhibitors in left ventricular dysfunction : Does current clinical dosing provide optimal benefit? / Pinto, YM; van Geel, PP; Alkfaji, H; van Veldhuisen, DJ; van Gilst, WH.

In: Journal of Cardiovascular Pharmacology, Vol. 34, 08.1999, p. S13-S17.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Pinto YM, van Geel PP, Alkfaji H, van Veldhuisen DJ, van Gilst WH. Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit? Journal of Cardiovascular Pharmacology. 1999 Aug;34:S13-S17.


BibTeX

@article{69eb6fa46e31404fbbff99f724d64e1b,
title = "Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit?",
abstract = "In the present review, we discuss the role of clinical dosing of angiotensin converting enzyme (ACE) inhibitors in the treatment of left ventricular dysfunction. Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established. However, it is unclear whether the doses used in clinical trials translate directly into daily practice. Several reasons may cause differences between clinical practice and controlled trials: (1) clinical trials used higher doses than in normal practice; (2) some patients may be relatively 'resistant' to ACE inhibition; and/or (3) ACE activity increases during ACE inhibitor therapy and may provide escape mechanisms when the drug regimen is not strictly adhered to. Therefore, it is of interest that recent trials suggest that only the higher doses of ACE inhibition are clinically efficacious. In conclusion, it is suggested that optimal benefit from treatment with an ACE inhibitor in patients with left ventricular dysfunction requires sufficient and frequent dosing of the ACE inhibitor, e.g., enalapril 10 mg twice daily or captopril 25 mg three times daily.",
keywords = "ACE inhibitors, left ventricular dysfunction, clinical trials, genetics, treatment, ANGIOTENSIN-CONVERTING-ENZYME, CHRONIC HEART-FAILURE, MYOCARDIAL-INFARCTION, II FORMATION, CAPTOPRIL, ENALAPRIL, POLYMORPHISM, ALDOSTERONE, MORTALITY, SURVIVAL",
author = "YM Pinto and {van Geel}, PP and H Alkfaji and {van Veldhuisen}, DJ and {van Gilst}, WH",
year = "1999",
month = aug,
language = "English",
volume = "34",
pages = "S13--S17",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
note = "ACE Inhibition and Vascular Protection in Hypertension Spirapril Symposium ; Conference date: 25-08-1998",

}

RIS

TY - JOUR

T1 - Dosing of ACE inhibitors in left ventricular dysfunction

T2 - ACE Inhibition and Vascular Protection in Hypertension Spirapril Symposium

AU - Pinto, YM

AU - van Geel, PP

AU - Alkfaji, H

AU - van Veldhuisen, DJ

AU - van Gilst, WH

PY - 1999/8

Y1 - 1999/8

N2 - In the present review, we discuss the role of clinical dosing of angiotensin converting enzyme (ACE) inhibitors in the treatment of left ventricular dysfunction. Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established. However, it is unclear whether the doses used in clinical trials translate directly into daily practice. Several reasons may cause differences between clinical practice and controlled trials: (1) clinical trials used higher doses than in normal practice; (2) some patients may be relatively 'resistant' to ACE inhibition; and/or (3) ACE activity increases during ACE inhibitor therapy and may provide escape mechanisms when the drug regimen is not strictly adhered to. Therefore, it is of interest that recent trials suggest that only the higher doses of ACE inhibition are clinically efficacious. In conclusion, it is suggested that optimal benefit from treatment with an ACE inhibitor in patients with left ventricular dysfunction requires sufficient and frequent dosing of the ACE inhibitor, e.g., enalapril 10 mg twice daily or captopril 25 mg three times daily.

AB - In the present review, we discuss the role of clinical dosing of angiotensin converting enzyme (ACE) inhibitors in the treatment of left ventricular dysfunction. Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established. However, it is unclear whether the doses used in clinical trials translate directly into daily practice. Several reasons may cause differences between clinical practice and controlled trials: (1) clinical trials used higher doses than in normal practice; (2) some patients may be relatively 'resistant' to ACE inhibition; and/or (3) ACE activity increases during ACE inhibitor therapy and may provide escape mechanisms when the drug regimen is not strictly adhered to. Therefore, it is of interest that recent trials suggest that only the higher doses of ACE inhibition are clinically efficacious. In conclusion, it is suggested that optimal benefit from treatment with an ACE inhibitor in patients with left ventricular dysfunction requires sufficient and frequent dosing of the ACE inhibitor, e.g., enalapril 10 mg twice daily or captopril 25 mg three times daily.

KW - ACE inhibitors

KW - left ventricular dysfunction

KW - clinical trials

KW - genetics

KW - treatment

KW - ANGIOTENSIN-CONVERTING-ENZYME

KW - CHRONIC HEART-FAILURE

KW - MYOCARDIAL-INFARCTION

KW - II FORMATION

KW - CAPTOPRIL

KW - ENALAPRIL

KW - POLYMORPHISM

KW - ALDOSTERONE

KW - MORTALITY

KW - SURVIVAL

M3 - Article

VL - 34

SP - S13-S17

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

Y2 - 25 August 1998

ER -

ID: 3816323